Standard Engineering Technology Ltd

- No mention of any new fundraising through debt or equity was made during the call. - The company is currently net debt-free with a cash reserve of INR266 crores, indicating strong financial health. - Capex plans include INR130-200 crores investment over the next 18-24 months, primarily funded through internal accruals and IPO proceeds (INR40 crores allocated to existing facilities). - Management indicated focus is on capex investments rather than new fundraising at this time. - They are open to future acquisition opportunities but did not specify any fundraising plans for those. - Overall, current strategy emphasizes funding growth through operational cash flows and existing cash reserves without raising new debt or equity.

- Current capex includes INR130 crores invested in a new Greenfield project over 18-24 months to build a 5.5 lakh sq. ft. plant on 36 acres, focusing on heavy engineering, petrochemicals, and multi-product manufacturing. - Additional INR40 crores is planned for existing facilities upgrades. - Total upcoming investment is approximately INR170-200 crores. - This capex is expected to boost revenue to INR3,000 crores consol basis once complete. - Separate shell and tube heat exchanger unit is being established and will start partial production by Q4 FY '26 and full production from April 2027. - INR130 crores capex is anticipated to achieve an 8-9 times asset turnover post-expansion. - The company has a 20-year global strategic partnership with GL HAKKO Japan and other international partners to enhance market and product reach. - The focus is on expanding into petrochemicals, heavy engineering, and increasing export participation.

- Expected revenue growth of 20%-25% in FY '26 driven by increased pharma and chemical industry capex. - Incremental revenue potential up to INR 3,000 crores following planned capex investments of INR 130-200 crores. - Launch and scaling of new products (shell and tube heat exchangers, conductivity glass-lined reactors) to add 30%-40% revenue growth to glass lining division. - Heat exchanger production capacity starting at 200 units per month from January 2027, expandable to 600-700 units per month based on demand. - Revenue from conductivity glass reactors anticipated post certification, expected to be a game changer in the industry. - Export market expansion with global partners boosting sales outside India and Japan. - Completion of 5.5 lakh sq.ft. Greenfield plant in 18-24 months targeting heavy engineering and petrochemical sectors, enabling new revenue streams.

- The company targets 20%-25% revenue growth in FY '26, driven by increased pharma capex, chemical sector growth, and new product launches like shell and tube heat exchangers and conductivity glass. - Expected EBITDA margins are strong, aiming to maintain between 18%-20%, supported by cost savings and export growth. - Expansion includes INR130-200 crore capex in new facilities (Greenfield project with 5.5 lakh sq ft plant), targeting diversification into petrochemicals and heavy engineering. - Current EBITDA margin is around 19.1%, with robust operational discipline. - PAT margin in FY '25 was 11.0%, growing 14.4% year-on-year, with expectations to sustain or improve margins through efficiency and new products. - Production ramp-up: Shell & tube heat exchangers full production expected from April 2027, contributing 30%-40% revenue growth in glass lining division. - The company is net debt-free with strong cash reserves of INR266 crores, supporting future growth investments.

- The company has a strong order book for the coming year, with approximately 80% of orders already booked based on fast delivery capabilities. - Recent product launches, including shell and tube heat exchangers and conductivity glass-lined reactors, have received robust market response. - Within 15 days of launching shell and tube heat exchangers, 150 orders have been received, with deliveries expected over 4 months. - The heat exchanger business is fully booked for the next 9 months, indicating strong demand. - The Greenfield expansion project (5.5 lakh sq ft plant) is expected to be completed in 18-24 months, supporting future order fulfillment. - Order booking momentum is positive, with anticipated 20%-25% revenue growth in FY '26 backed by increased inquiries and confirmed orders from pharma and chemical sectors. - Export consignments deferred previously are expected to contribute positively in Q1 FY '26. - Overall, the order pipeline remains robust with optimistic revenue forecasts.